Compare Allstate Corp (ALL) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs Canopy Growth Corp — how do they compare? Allstate Corp trades at $257.7 (market cap $66.31B), while Canopy Growth Corp trades at $1.03 (market cap $421.10M). The key difference: Allstate Corp is far larger — about 157.5× Canopy Growth Corp's market cap, and Allstate Corp pays a 1.65% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| ALL | CGC | |
|---|---|---|
Market Cap | $66.31B | $421.10M |
Sector | Financials | Health |
52-Week High | $275.11 | $1.92 |
52-Week Low | $190.00 | $0.86 |
Enterprise Value | $74.96B | $378.55M |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $256.62, down 4.84% over 24 hours, but maintains a bullish technical signal with strong fundamental performance. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. Recent news highlights institutional buying and positive analyst coverage, though some caution exists on sustainability.
The outlook remains positive with a consensus price target of $266.47, offering potential upside. Key risks include sustainability of underwriting margins and macroeconomic sensitivity. Earnings momentum and valuation metrics support a favorable investment case, but investors should monitor competitive pressures and catastrophe loss trends.
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
